000			01957nam a2200313 4500
001			ESSALUD
005			20260804124411.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aHauser, Stephen L. _eAutor _953675
245			_aAdvances in multiple sclerosis
300			_apáginas: 54-68
520			_aMultiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing episodes of neurologic dysfunction and often gradual disease progression. The immune system primarily targets myelin, the protective covering of nerve fibers, leading to inflammation and damage, and secondary neurodegeneration is a major cause of long-term disability. Common symptoms include vision problems, sensory disturbances, muscle weakness, balance difficulties, and bladder dysfunction. Important advances in treatment have improved outcomes in patients with relapsing forms of multiple sclerosis, particularly through highly effective immune-modifying therapies such as CD20-targeting monoclonal antibodies. However, treatment options for progressive forms remain limited, which highlights the need for therapies that can prevent progression and promote myelin repair. Comprehensive symptom management and lifestyle support are also essential to maintaining quality of life and reducing disability.
650			_aALERGIA _97055
650			_aINMUNOLOGÍA GENERAL _953664
650			_aENFERMEDAD AUTOINMUNE _953665
650			_aMEDICINA CLINICA GENERAL _953666
650			_aENFERMEDAD INFLAMATORIA _953667
650			_aESCLEROSIS MULTIPLE _914091
650			_aGENETICA _91105
650			_aREUMATOLOGÍA _97490
650			_aNEUROLOGÍA
650			_aNEUROCIRUGÍA _97782
650			_aOFTALMOLOGÍA _932364
773	0		_022717 _922634 _dMassachusetts NEJM Group _oNEJM001 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-07-31 _zsqb
999			_c22725 _d22725